Antibody against mutant α-actinin-4
An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.
1. An antibody against mutant α-actinin-4 comprising an amino acid sequence with at least one amino acid residue substitution in the region between positions 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region and does not bind to constitutively expressed α-actinin-4, wherein the amino acid sequence with substituted amino acid residue(s) is represented by DIVGTLRPDEKAIMTYVSC (SEQ ID NO: 4).
2. The antibody according to claim 1 , wherein the antibody is a monoclonal antibody.
3. The antibody according to claim 2 , which is produced by a hybridoma having Accession No. NITE BP-1140.
4. An antibody binding to an epitope, to which the antibody according to claim 2 binds.
5. The antibody according to claim 2 , wherein the antibody is a chimeric antibody, a humanized antibody or a reconstituted human antibody.
6. A fragment of the antibody according to claim 1 .
7. A hybridoma producing the antibody according to claim 2 .
8. A hybridoma having Accession No. NITE BP-1140.
9. A method for preparing an antibody against mutant α-actinin-4 which does not bind to constitutively expressed α-actinin-4, which comprises the steps of:
(a) immunizing a non-human mammal with a partial peptide comprising the amino acid sequence of the region between positions 245 and 263 in the amino acid sequence of α-actinin-4, wherein the partial peptide has at least one amino acid residue substitution in said region;
(b) collecting the antibody from the non-human mammal; and
(c) selecting an antibody which binds an amino acid sequence with at least one amino acid residue substitution in the region between positions 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region and does not bind to constitutively expressed α-actinin-4.
10. A method for preparing a monoclonal antibody against mutant α-actinin-4 which does not bind to constitutively expressed α-actinin-4, which comprises the steps of:
(a) immunizing a non-human mammal with a partial peptide comprising the amino acid sequence of the regionbeetween positions 245 and 263 in the amino acid sequence of α-actinin-4, wherein the partial peptide has at least one amino acid residue substitution in said region;
(b) collecting antibody-producing cells from the immunized non-human mammal of step (a);
(c) allowing the antibody-producing cells obtained in step (b) to be fused with myeloma cells;
(d) collecting the antibody from the fusion cells obtained in step (c); and
(e) selecting an antibody which binds an amino acid sequence with at least one amino acid residue substitution in the region between positions 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region and does not bind to constitutively expressed α-actinin-4.
11. The method according to claim 9 , wherein the non-human mammal is a GANP transgenic non-human mammal.
12. A method for detecting mutant α-actinin-4, which is characterized by reacting the antibody according to claim 1 or an antigen-binding fragment thereof with a biological sample to thereby detect mutant α-actinin-4.
13. A reagent for tumor detection or diagnosis, which comprises the antibody according to claim 1 or a fragment thereof.
14. The reagent according to claim 13 , wherein the tumor is lung primary high-grade neuroendocrine tumor.
15. An antitumor pharmaceutical composition, which comprises a substance inhibiting the functions of mutant α-actinin-4 comprising an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the substance inhibiting the functions of mutant α-actinin-4 is the antibody according to claim 1 or a fragment thereof.
16. An antitumor pharmaceutical composition, which comprises a substance inhibiting the functions of mutant α-actinin-4 comprising an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the substance inhibiting the functions of mutant α-actinin-4 is the antibody according to claim 1 or a fragment thereof.
17. The pharmaceutical composition according to claim 15 , wherein the tumor is lung primary high-grade neuroendocrine tumor.